Most Read Articles
Stephen Padilla, 6 days ago
Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
3 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.
Yesterday
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.

Rituximab for systemic sclerosis safely improves skin fibrosis

06 Jun 2019

Treatment with rituximab in patients with systemic sclerosis (SSc) is relatively safe and produces improvements in skin but not lung fibrosis, a study has shown.

Researchers used data from the European Scleroderma Trials and Research (EUSTAR) network and identified 254 SSc patients (median age, 51 years; 71 percent female) treated with rituximab. They assessed the safety of the drug and its effect on skin fibrosis improvement, lung fibrosis worsening and steroids use.

In the cohort, rituximab was indicated for lung involvement in 58 percent of patients and for skin involvement in 32 percent. After a median follow-up of 2 years, the majority (70 percent) of patients did not develop any side effects.

An analysis comparing the 254 rituximab-treated SSc patients with 9,575 propensity-score matched patient controls showed rituximab treatment to be associated with a higher likelihood of skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; odds ratio [OR], 2.79, 95 percent CI, 1.47–5.32; p=0.002).

On the other hand, there were no significant between-group differences observed in rates of forced vital capacity (FVC) >10 percent (OR, 1.03, 0.55–1.94; p=0.93) or in carbon monoxide diffusing capacity (DLCO) <70 percent (OR, 1.68, 0.68–4.2; p=0.27).

Compared with controls, rituximab-treated patients were more likely to stop or reduce steroids (OR, 2.34, 1.56–3.53; p<0.0001). Furthermore, patients who received mycophenolate mofetil concomitantly tended to have better outcomes than those who received rituximab alone (delta FVC: OR, 3, 0.66–5.35; p=0.012) and controls (OR, 5.22, 0.83–9.62; p=0.019).

The study was limited by its observational design, according to researchers, adding that the potential stabilization of lung fibrosis by rituximab has to be addressed in a randomized trial.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 6 days ago
Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
3 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.
Yesterday
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.